Who Owns a Custom Supplement Formula? Questions to Settle Before Development

Quick Answer

Paying a development fee does not by itself prove that a brand owns every formula, process, improvement, or document created during a supplement project. Ownership, license scope, exclusivity, confidentiality, background know-how, brand assets, manufacturing-record custody, and transfer materials are separate issues. Define each one in writing before sensitive disclosure or paid development begins.

What Does “the Formula” Include?

Buyers often use “formula” to mean several different things:

• The ingredient list shown on the label
• The amount of each ingredient per serving
• The full manufacturing composition, including ingredient forms and excipients
• Supplier or grade restrictions
• Target specifications and acceptance criteria
• Processing instructions and operating parameters
• Flavor system, sensory targets, and masking approach
• Samples, test results, and development records
• Improvements made during scale-up

These elements may not have the same owner, confidentiality status, or transfer right. A brand can own its trademark and packaging artwork while using a manufacturer-owned base formula. It can own a formula specification while the manufacturer retains background process know-how. It can also receive a license to use a formula without receiving ownership.

The contract should define the subject matter precisely enough that both parties know what the word “formula” covers.

Ownership vs. License vs. Exclusivity

These terms are related but not interchangeable.

WIPO explains that an IP assignment transfers ownership, while a license authorizes use while the owner retains ownership. That distinction should be reflected in the project agreement rather than inferred from invoice language such as “custom formulation fee.”

White Label, Private Label, and Custom Formula Differences

White label or ready formula

A manufacturer may offer an established formula to more than one brand. The buyer typically receives the right to market the finished product under its own brand, subject to the agreed commercial terms. The base formula may remain the manufacturer’s or another party’s property.

Private-label adaptation

The project may change flavor, color, serving, package, or selected ingredients within an available platform. The agreement should state whether the adaptation is exclusive, who owns the modification, and whether the base formula remains outside any assignment.

Custom development

The parties may create a new formula against the brand’s brief. Even here, “custom” does not automatically answer ownership. The agreement should distinguish brand-provided inputs, manufacturer background know-how, newly created work, improvements, and permitted reuse.

Because these labels are used inconsistently in the market, define the actual rights instead of relying on the label alone.

What an NDA Protects—and What It Does Not Decide

A non-disclosure agreement controls the handling and permitted use of confidential information. It can define covered information, recipients, purpose, exclusions, security expectations, disclosure required by law, duration, return or destruction, and remedies.

An NDA does not automatically:

• Transfer formula ownership
• Create product exclusivity
• Assign improvements
• Grant a manufacturing license
• Define record-access rights
• Require transfer assistance to another manufacturer
• Determine ownership of artwork or trademarks

WIPO’s trade-secret guidance emphasizes defining confidential information, limiting use to the agreed purpose, taking reasonable protection measures, and agreeing in advance who controls newly created work. A project may need both an NDA and a development or manufacturing agreement with explicit IP terms.

Background IP vs. Foreground IP

Background IP is the knowledge, technology, formula platform, process, documentation, method, or other intellectual asset a party already owns or controls before the project, or develops outside the project.

Foreground IP is work created within the defined project. The agreement should state whether foreground IP is owned by the brand, the manufacturer, jointly, or by the creator with a license to the other party.

The boundary matters in supplement development because the manufacturer may apply general formulation experience, sensory techniques, processing knowledge, or standard excipient systems across many customers. A brand may contribute a unique formula, market insight, ingredient combination, or prior research. Neither side should assume that paying for work automatically transfers the other party’s background assets.

Questions to define include:

• What each party brings into the project
• What work is expected to be created
• Who owns improvements or derivatives
• Whether either party may reuse general learnings
• Whether a license is needed to manufacture and sell the product
• What happens when the agreement ends

Brand Artwork, Trademarks, and Packaging Files

Brand assets are separate from the product formula. The agreement should identify ownership and permitted use of:

• Brand name and trademarks
• Logos and visual identity
• Label artwork and editable source files
• Packaging dielines and structural designs
• Product photography and marketing copy
• Barcodes and retailer identifiers
• Print plates, cylinders, or tooling where applicable

A brand may own the logo but not the package dieline created by a component supplier. It may own final artwork but need a license for stock images or fonts. It may pay for tooling without automatically obtaining physical possession or unrestricted use. These questions belong in the commercial agreement and purchase documentation.

Manufacturer Know-How and Process Parameters

A formula specification and a manufacturing process are not always the same asset. Mixing order, environmental controls, equipment settings, processing windows, in-process checks, and scale-up experience may contain manufacturer know-how.

If the brand expects to transfer production later, the parties should define which technical package will be provided, what remains confidential to the manufacturer, and whether transfer support is included. A promise that “you own the formula” is incomplete if it does not state whether the brand receives enough controlled information to reproduce the product elsewhere.

At the same time, no buyer should assume a right to a manufacturer’s unrelated process platform, equipment know-how, supplier network, or other customers’ information.

Manufacturing Records: Ownership, Custody, and Access

Manufacturing records are also separate from formula ownership. Under U.S. dietary supplement CGMP requirements, manufacturers must create and retain defined records relating to production and process controls. The legal recordkeeping obligation does not by itself answer every commercial question about who receives copies, when, in what format, or at what level of detail.

The quality or manufacturing agreement should address:

• Which records are created
• Who has legal custody
• Retention period and storage format
• Routine access vs. access for investigations, audits, or regulatory requests
• Redaction of unrelated confidential information
• Timing and method for providing approved copies
• Records available after termination
• Costs for retrieval, special reports, or transfer support

Do not use “formula ownership” as a substitute for a record-access clause.

Can a Brand Move Its Formula to Another Manufacturer?

Transferability depends on the rights and information the brand actually holds. A workable transfer may require more than an ingredient list. It may involve controlled specifications, ingredient grades, suppliers, process-relevant attributes, packaging configuration, test methods, acceptance criteria, samples, change history, and authorized technical support.

Before development begins, ask:

1. Does the brand own the formula, or hold a license?
2. Is the license transferable or sublicensable?
3. What background IP is excluded?
4. What technical documents will the brand receive?
5. What records remain in manufacturer custody?
6. Are process instructions included or excluded?
7. Who owns improvements made during scale-up?
8. Does termination trigger return, destruction, continuing confidentiality, or transition support?

Even when transfer is contractually allowed, a new manufacturer must conduct its own feasibility, sourcing, quality, and process review. Transferability is not a guarantee that another facility can reproduce the product without redevelopment.

A Step-by-Step Rights Discussion Before Development

1. Classify the project. Ready formula, adaptation, brand-supplied formula, or new custom development.
2. Inventory background inputs. List brand and manufacturer materials that predate the project.
3. Sign an appropriate confidentiality agreement. Do this before sensitive disclosure where needed.
4. Define the development output. Formula specification, samples, test data, artwork, process work, or another deliverable.
5. Allocate foreground rights. State ownership, license, exclusivity, improvements, and reuse rights.
6. Define records and transfer materials. Separate manufacturing-record custody from brand deliverables.
7. Set payment and milestone conditions. Identify whether rights change only after full payment or another event.
8. Plan termination. Cover continuing confidentiality, remaining inventory, unused packaging, data, documents, and transition support.
9. Obtain qualified legal review. Apply the governing law and the actual business arrangement.

OEM vs. ODM vs. Private Label Rights Discussion

Contract Discussion Checklist

• [ ] Project model and exact definition of “formula”
• [ ] Brand background IP
• [ ] Manufacturer background IP and know-how
• [ ] Newly created formula, improvements, and derivative work
• [ ] Ownership vs. license
• [ ] Exclusive, sole, or nonexclusive scope
• [ ] Territory, channel, product, customer, and term limits
• [ ] Confidential-information definition and permitted use
• [ ] Authorized employees, affiliates, labs, and suppliers
• [ ] Brand name, trademark, artwork, dieline, and source-file rights
• [ ] Test data and development-record rights
• [ ] Manufacturing-record custody and access
• [ ] Transfer package and transition support
• [ ] Rights after termination
• [ ] Return or destruction of confidential materials
• [ ] Unused custom ingredients and packaging
• [ ] Payment milestones tied to any assignment or license
• [ ] Governing law, dispute process, and qualified legal review

How Aidacru Fits Into the Discussion

Aidacru works with B2B buyers considering private-label, ODM, and OEM supplement projects. Before custom development, the commercial discussion should identify the formula source, development status, target market, requested ownership or license outcome, confidentiality needs, expected documents, and any future transfer scenario.

This article does not state that Aidacru assigns, licenses, or withholds any specific right in every project. Actual ownership, exclusivity, confidentiality, record access, pricing, and transfer obligations are determined by the applicable written agreements and project scope.

Procurement FAQs

1. If I pay a formulation fee, do I automatically own the formula?

Do not assume so. The fee may cover development services without assigning all resulting IP. The written agreement should identify the deliverable, ownership or license, excluded background IP, and the event that makes any transfer effective.

2. Does an NDA transfer intellectual property?

Usually an NDA controls confidentiality and permitted use; it is not automatically an assignment. Ownership, licenses, exclusivity, improvements, and transfer rights should be addressed expressly in the appropriate agreement.

3. Can a white-label formula be exclusive?

Only if the rights holder agrees to a defined exclusivity arrangement. Clarify scope, territory, channel, term, performance conditions, and whether exclusivity covers the base formula, an adaptation, or only brand presentation.

4. Can I take process parameters to another manufacturer?

That depends on the agreement and the nature of the information. Process parameters may include manufacturer background know-how or project-created work. Define the transfer package and excluded information before development.

5. Does the brand own its label artwork?

The brand may own or license its artwork, but confirm rights to editable files, dielines, fonts, stock assets, structural designs, plates, and tooling. Ownership of the trademark does not answer every production-file question.

6. Is ownership of batch records the same as ownership of the formula?

No. Record creation, retention, custody, and access are separate from formula ownership. Address records in the quality and manufacturing agreements, including access after termination.

7. What should the brand receive when the relationship ends?

The agreement should list the applicable formula or specification files, approved artwork, brand-owned materials, permitted development data, record copies, remaining custom inventory, and any transition support. Avoid relying on a general promise to “return everything.”

8. When should a lawyer review the agreement?

Obtain qualified legal advice before signing terms that affect valuable formulas, trade secrets, exclusivity, assignment, licensing, cross-border rights, or future transfer. The correct answer depends on jurisdiction and contract language.

Key Takeaways

• “The formula” may include several different technical and commercial assets.
• Ownership, license, exclusivity, and confidentiality are separate rights.
• An NDA protects information but does not automatically assign IP.
• Background know-how, new project work, artwork, manufacturing records, and transfer materials need separate treatment.
• Define rights in writing before sensitive disclosure or paid development begins.

Project CTA

Send Aidacru your proposed project model, formula source, development status, target market, ownership or exclusivity expectation, confidentiality needs, required records, and potential future transfer scenario. We can organize the commercial and technical questions for discussion; all legal conclusions and contract language should be confirmed by qualified counsel for the applicable jurisdiction.

Recommended Internal Links

• Supplement Manufacturing Record Access
• Dietary Supplement Quality Agreement
• Custom Supplement Formulation vs. White Label
• Contract Supplement Manufacturer Qualification

Technical References

• WIPO: IP Assignment and Licensing
• WIPO: Trade Secrets FAQs
• WIPO Guide to Trade Secrets and Innovation—Trade Secret Management
• 21 CFR Part 111—Dietary Supplement CGMP

Legal note: This article provides general B2B procurement education and is not legal advice. Ownership and confidentiality outcomes depend on the facts, governing law, and signed agreements. Consult qualified counsel before relying on any IP or contract position.

Discuss your supplement project with Aidacru